Project description:Transcriptional profiling of siRNA-mediated inhibition of CDC7 in IMR90 primary diploid fibroblasts derived from embryonic lung tissue.
Project description:Expression profiling was done of FOXK2 depletion by siRNA transfection. This was done on the human osteosarcoma U2OS cell line (which stably expresses FOXK2).
Project description:We report here the DNA-binding profiles for all human and mouse ETS factors, which we generated using two different methods: a high-throughput microwell-based transcription factor DNA-binding specificity assay, and protein binding microarrays (PBMs). Both approaches reveal that the ETS binding profiles cluster into four distinct classes, and that all ETS factors linked to cancer, ERG, ETV1, ETV4 and FLI1, fall into just one of these classes. We identify amino acid residues that are critical for the differences in specificity between all the classes, and confirm the specificities in vivo using chromatin immunoprecipitation followed by sequencing (ChIP-seq) for a member of each class. To determine whether the ChIP-seq peaks were near genes regulated by the respective ETS-factors, we used RNAi to downregulate EWS-FLI1 in SK-N-MC Ewing's sarcoma cells. The results indicate that even relatively small differences in in vitro binding specificity of a TF contribute to site selectivity in vivo.
Project description:In this experiment, we aim to examine the role of NAT10 inhibition in Hutchinson-Gilford progeria syndrome (HGPS), a rare but devastating premature ageing syndrome caused by a mutation in the LMNA gene. NAT10 inhibition improves HGPS cellular phenotypes by releasing Transportin-1 (TNPO1) from the cytoplasm, restoring the TNPO1 pathway and allowing hnRNPA1 and NUP153 nuclear import, TPR anchorage at the nuclear pore complexes and RanGTP gradient re-balancing. We have promoted NAT10 inhibition by two ways in normal or patient derived primary skin fibroblasts; the NAT10 inhibitor Remodelin, and an siRNA directly targeting NAT10 (siNAT10). In addition, we have also used an siRNA against TNPO1 and a combined siTNPO1 and siNAT10 treatment. This is a 2-factor design, with treatment (Remodelin vs untreated, or siNAT10 vs siCT) and condition (HGPS vs normal fibroblasts) as the two conditions. Transcriptional profiling was performed using HumanHT-12 v4 Expression BeadChip microarrays, and all conditions were run in triplicate.
Project description:Expression profiling was done of exposure to phorbol myristate acetate -PMA and FOXK2 depletion by siRNA transfection. This was done on the human osteosarcoma U2OS cell line which stably expresses FOXK2. PMA is an inducer of AP1 activity.
Project description:We profiled global gene expression in primary human umbilical vein endothelial cells to determine the gene expression changes associated with knocking down PKM2 and p53. We identified a p53 dependent transcriptional response that remodels metabolism in cells lacking p53, thus limiting cell growth. Human Umbilical Vein Endothelial Cells were transfected with siRNA duplexes targeting PKM2 and / or p53, RNA was extracted and subjected to RNA sequencing
Project description:Gastric cancer cell line AGS was treated with suberoylanilide hydroxamic acid (SAHA) for 24 hours. Microarray analysis was done to explore the differentially expressed genes betweenSAHA treated and control cells.
Project description:To investigate the role of SCAI (suppressor of cancer cell invasion) on gene expression, MDAMB-231 mammary carcinoma cells were transfected by SCAI siRNA and global mRNA expression profiling was performed in comparison to mock siRNA transfecte cells. Experiments were performed in three independent biological replica.
Project description:MiR-10a inhibits colon cancer invasion and metastasis. To search the candidate target genes of miR-10a, SW480 cells were transfected with miR-10a blockage to suppress miR-10a activity and the differentially expressed genes were detected by cDNA microarray analysis. Some of the up-regulated genes may be candidate target genes of miR-10a.